hiPSC-derived bone marrow milieu identifies a clinically actionable driver of niche-mediated treatment resistance in leukemia

Pal, Deepali, Blair, Helen J., Parker, Jessica, Hockney, Sean, Beckett, Melanie, Singh, Mankaran, Tirtakusuma, Ricky, Nelson, Ryan, McNeill, Hesta, Angel, Sharon Hanmy, Wilson, Aaron, Nizami, Salem, Nakjang, Sirintra, Sankar, Shalini, Zhou, Peixun, Schwab, Claire, Sinclair, Paul B., Russell, Lisa J., Coxhead, Jonathan, Halsey, Christina, Allan, James M., Harrison, Christine J., Moorman, Anthony Vincent, Olaf, Heidenreich and Vormoor, Josef (2022) hiPSC-derived bone marrow milieu identifies a clinically actionable driver of niche-mediated treatment resistance in leukemia. Cell Reports Medicine. ISSN 2666-3791 (In Press)

[img] Text
CR-MEDICINE-D-21-00480_R3.pdf - Accepted Version
Restricted to Repository staff only until 3 September 2022.
Available under License Creative Commons Attribution 4.0.

Download (3MB) | Request a copy
Official URL: https://doi.org/10.1016/j.xcrm.2022.100717


Leukaemia cells re-program their microenvironment to provide proliferation support and protection from standard chemotherapy, molecularly targeted therapies, and immunotherapy. Although much is becoming known about molecules that drive niche-dependent treatment resistance; means of targeting these in the clinics has remained a key obstacle. To address this challenge, we have developed human induced pluripotent stem cell engineered niches ex vivo to reveal insights into druggable cancer-niche dependencies. We show that mesenchymal (iMSC) and vascular niche-like (iANG) cells support ex vivo proliferation of patient-derived leukaemia cells, impact dormancy and mediate therapy resistance. iMSC protected both non-cycling and cycling blasts against dexamethasone treatment while iANG protected only dormant blasts. Leukaemia proliferation and protection from dexamethasone induced-apoptosis was dependent on direct cell-cell contact and mediated by CDH2. To explore the therapeutic potential of disrupting this cell-cell interaction, we tested the CDH2 antagonist ADH-1 (previously in phase I / II for solid tumours) in a very aggressive patient-derived xenograft leukaemia mouse model. ADH-1 showed high in vivo efficacy. ADH-1/ dexamethasone combination therapy was superior to dexamethasone alone with no ADH1 conferred additional toxicity. These findings provide a proof-of-concept starting point to develop novel, potentially safer therapeutics that target niche-mediated cancer cell dependencies in haematological malignancies.Summary CDH2 mediated niche-dependent cancer proliferation and treatment resistance is clinically targetable via ADH-1, a low toxic agent that could be potentially repurposed for future clinical trials in acute leukaemia.Competing Interest StatementThe authors have declared no competing interest.

Item Type: Article
Subjects: B100 Anatomy, Physiology and Pathology
B900 Others in Subjects allied to Medicine
C700 Molecular Biology, Biophysics and Biochemistry
Department: Faculties > Health and Life Sciences > Applied Sciences
Related URLs:
Depositing User: Elena Carlaw
Date Deposited: 03 Aug 2022 10:49
Last Modified: 04 Aug 2022 08:01
URI: http://nrl.northumbria.ac.uk/id/eprint/49710

Actions (login required)

View Item View Item


Downloads per month over past year

View more statistics